Wang YJ, Li ZX, Gu HQ, Zhai Y, Jiang Y, Zhao XQ et al (2020) China Stroke statistics 2019: a Report from the National Center for Healthcare Quality Management in Neurological Diseases, China National Clinical Research Center for Neurological Diseases, the Chinese Stroke Association, National Center for Chronic and non-communicable Disease Control and Prevention. Stroke and Vascular Neurology 5(3):211–239. Chinese Center for Disease Control and Prevention and Institute for Global Neuroscience and Stroke Collaborationshttps://doi.org/10.1136/svn-2020-000457

Article  PubMed  PubMed Central  Google Scholar 

Sirimarco G, Lavallee PC, Labreuche J, Meseguer E, Cabrejo L, Guidoux C et al (2013) Overlap of Diseases underlying ischemic Stroke: the ASCOD phenotyping. Stroke 44(9):2427–2433. https://doi.org/10.1161/STROKEAHA.113.001363

Article  PubMed  Google Scholar 

Lavallée PC, Charles H, Albers GW, Caplan LR, Donnan GA, Ferro JM et al (2023) Effect of Atherosclerosis on 5-year risk of major vascular events in patients with transient ischaemic Attack or minor ischaemic Stroke: an international prospective cohort study. Lancet Neurol 22(4):320–329. https://doi.org/10.1016/s1474-4422(23)00067-4

Article  PubMed  Google Scholar 

Vergallo R, Crea F (2020) Atherosclerotic Plaque Healing. N Engl J Med 383(9):846–857. https://doi.org/10.1056/NEJMra2000317

Article  CAS  PubMed  Google Scholar 

Amarenco P, Bogousslavsky J (2006) and, High-dose atorvastatin after Stroke or transient ischemic Attack. J Vasc Surg.

Ntaios G, Milionis H (2019) Low-density lipoprotein cholesterol lowering for the prevention of cardiovascular outcomes in patients with ischemic Stroke. Int J Stroke: Official J Int Stroke Soc 14(5):476–482. https://doi.org/10.1177/1747493019851283

Article  Google Scholar 

Amarenco P, Kim JS, Labreuche J, Charles H, Abtan J, Béjot Y et al (2020) A comparison of two LDL cholesterol targets after ischemic Stroke. N Engl J Med 382(1):9. https://doi.org/10.1056/NEJMoa1910355

Article  CAS  PubMed  Google Scholar 

Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P et al (2015) Ezetimibe added to statin therapy after Acute Coronary syndromes. N Engl J Med 372(25):2387–2397. https://doi.org/10.1056/NEJMoa1410489

Article  CAS  PubMed  Google Scholar 

Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N et al (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomized trialCholesterol Treatment trialists’ (CTT) CollaborationLancet20103761670168110.1016/S0140-6736(10)61350-5298822421067804. Lancet 376(9753):1670–1681

Article  CAS  PubMed  Google Scholar 

HPS2-THRIVE randomized (2013) Placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 34(17):1279–1291. https://doi.org/10.1093/eurheartj/eht055

Article  CAS  Google Scholar 

Shui-ping, Zhao Bi-lian (2014) Yu, Dao-quan, Peng, The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: results of the \ trial. Atherosclerosis.

Schuster S, Rubil S, Endres M, Princen HMG, Boeckel JN, Winter K et al Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice. Entific Reports

A KCK, A SW BGP, C CM (2019) Evolocumab for early reduction of LDLCholesterol levels in patients with Acute Coronary syndromes (EVOPACS). J Am Coll Cardiol 74(20):2452–2462

Article  Google Scholar 

[Chinese expert consensus on lipid management of very high-risk atherosclerotic cardiovascular disease patients] (2020) Zhonghua Xin xue guan bing za zhi. 48(4):280–286. https://doi.org/10.3760/cma.j.cn112148-20200121-00036

Wu Z, Wu D, Jiang J, Chen A, Zheng DD, Li J et al (2020) Efficacy and safety of xuezhikang once per day versus two times per day in patients with mild to moderate hypercholesterolaemia (APEX study): a protocol for a multicentre, prospective randomised controlled, open-label, non-inferiority study. BMJ Open 10(5):e034585. https://doi.org/10.1136/bmjopen-2019-034585

Article  PubMed  PubMed Central  Google Scholar 

Santos RD, Ruzza A, Hovingh GK, Wiegman A, Mach F, Kurtz CE et al (2020) Evolocumab in Pediatric heterozygous familial hypercholesterolemia. N Engl J Med 383(14):1317–1327. https://doi.org/10.1056/NEJMoa2019910

Article  CAS  PubMed  Google Scholar 

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA et al (2017) Evolocumab and Clinical outcomes in patients with Cardiovascular Disease. N Engl J Med. :1713

Rosenson RS, Daviglus ML, Handelsman Y, Pozzilli P, Bays H, Monsalvo ML et al (2019) Efficacy and safety of evolocumab in individuals with type 2 Diabetes Mellitus: primary results of the randomised controlled BANTING study. Diabetologia.

Giugliano RP, Pedersen TR, Saver JL, Sever PS, Keech AC, Bohula EA et al (2020) Stroke Prevention with the PCSK9 (Proprotein Convertase Subtilisin-Kexin type 9) inhibitor Evolocumab added to statin in high-risk patients with stable Atherosclerosis. Stroke 51(5):1546–1554. https://doi.org/10.1161/STROKEAHA.119.027759

Article  CAS  PubMed  Google Scholar 

Zhang M, Deng Q, Wang L, Huang Z, Zhou M, Li Y et al (2018) Corrigendum to Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults: a nationally representative survey of 163,641 adults [Int. J. Cardiol. 260 (2018) 196–203]. Int J Cardiol 267:218. https://doi.org/10.1016/j.ijcard.2018.04.100

Article  PubMed  Google Scholar 

Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH (2007) Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, Rhabdomyolysis, and Cancer: insights from large randomized statin trials. Journal of the American College of Cardiology

Turan TN, Nizam A, Lynn MJ, Egan BM, Le NA, Lopes-Virella MF et al (2017) Relationship between risk factor control and vascular events in the SAMMPRIS trial. Neurology 88(4):379–385. https://doi.org/10.1212/wnl.0000000000003534

Article  PubMed  PubMed Central  Google Scholar 

Sillesen H, Amarenco P, Hennerici MG, Callahan A, Goldstein LB, Zivin J et al (2008) Atorvastatin reduces the risk of cardiovascular events in patients with carotid Atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive reduction in cholesterol levels (SPARCL) trial. Stroke 39(12):3297–3302. https://doi.org/10.1161/strokeaha.108.516450

Article  CAS  PubMed  Google Scholar 

Lau KK, Chua BJ, Ng A, Leung IY, Wong YK, Chan AH et al (2021) Low-density lipoprotein cholesterol and risk of recurrent vascular events in Chinese patients with ischemic Stroke with and without significant Atherosclerosis. J Am Heart Assoc 10(16):e021855. https://doi.org/10.1161/jaha.121.021855

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu L, Kong Q, Huang H, Xu S, Qu W, Zhang P et al (2023) Effect of PCSK9 inhibition in combination with statin therapy on intracranial atherosclerotic stenosis: a high-resolution MRI study. Front Aging Neurosci 15:1127534. https://doi.org/10.3389/fnagi.2023.1127534

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ameriso SF, Amarenco P, Pearce LA, Perera KS, Ntaios G, Lang W et al (2020) Intracranial and systemic Atherosclerosis in the NAVIGATE ESUS trial: recurrent Stroke risk and response to antithrombotic therapy. J Stroke Cerebrovasc Diseases: Official J Natl Stroke Association 29(8):104936. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.104936

Article  Google Scholar 

Ntaios G, Perlepe K, Sirimarco G, Strambo D, Eskandari A, Karagkiozi E et al (2019) Carotid plaques and detection of atrial fibrillation in embolic Stroke of undetermined source. Neurology 92(23):e2644–e52. https://doi.org/10.1212/WNL.0000000000007611

Article  PubMed  Google Scholar 

Ntaios G, Wintermark M, Michel P (2021) Supracardiac Atherosclerosis in embolic Stroke of undetermined source: the underestimated source. Eur Heart J 42(18):1789–1796. https://doi.org/10.1093/eurheartj/ehaa218

Article  CAS  PubMed  Google Scholar 

Ntaios G, Swaminathan B, Berkowitz SD, Gagliardi RJ, Lang W, Siegler JE et al (2019) Efficacy and safety of Rivaroxaban Versus aspirin in Embolic Stroke of undetermined source and Carotid Atherosclerosis. Stroke 50(9):2477–2485. https://doi.org/10.1161/STROKEAHA.119.025168

Article  CAS  PubMed  Google Scholar 

Oesterle A, Liao JK (2019) The Pleiotropic effects of statins - from coronary artery Disease and Stroke to Atrial Fibrillation and ventricular tachyarrhythmia. Curr Vasc Pharmacol 17(3):222–232. https://doi.org/10.2174/1570161116666180817155058

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yousuf A, McVey DG, Ye S (2022) Relationship between Red Meat Metabolite Trimethylamine N-oxide and Cardiovascular Disease. Heart and Mind 6(1):3–9. https://doi.org/10.4103/hm.hm_8_21

Article  Google Scholar 

Ntaios G, Papavasileiou V, Makaritsis K, Milionis H, Manios E, Michel P et al (2014) Statin treatment is associated with improved prognosis in patients with AF-related Stroke. Int J Cardiol 177(1):129–133. https://doi.org/10.1016/j.ijcard.2014.09.031

Article  CAS  PubMed  Google Scholar 

Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al (2018) AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary. Journal of the American College of Cardiology. 2018

François M, Colin B, Catapano AL, Koskinas KC, Manuela C, Lina B et al (2019) 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. (1):1

Sagris D, Ntaios G, Georgiopoulos G, Kakaletsis N, Elisaf M, Katsiki N et al (2020) Recommendations for lipid modification in patients with ischemic Stroke or transient ischemic Attack: a clinical guide by the Hellenic Stroke Organization and the Hellenic Atherosclerosis Society. Int J Stroke: Official J Int Stroke Soc 1747493020971970. https://doi.org/10.1177/1747493020971970

Hlatky MA (2019) A pound of Prevention? Assessing the value of new cholesterol-lowering Drugs. Annals of Internal Medicine